NEURON-Percepta

Neuron-percepta

CLAW

Neuroscience

Percepta® is a patent-protected brain health natural dietary supplement (active ingredients, PTI-00703® Cat’s claw and MemorTea® - a specific oolong tea extract). Cerebrum DAO will be supporting the development of near- and long-term solutions for targeting cognitive decline, memory loss and neurodegenerative diseases. The global market for brain health supplements is over $8.6b - most if not all lack clinical evidence to support efficacy. Percepta® has robust patent protection and highly promising research results. Percepta has the potential to be the category leader in this fast growing $8.6b market with human evidence to support outcomes and the funding of future studies that could lead to FDA botanical drug status which is the ultimate goal. This IP-NFT represents a world’s first tokenization of a robust patent portfolio and a world’s first tokenized crowdsale for a clinical evidence study. Success with this study can lead to future trials that create the potential for FDA botanical drug approval, potentially unlocking broad access to improve brain health globally.

Owned by

0x907Bb…35680

Contract:

0x93757…DaA21

Description

The global market for brain health supplements is over $8.6b - most if not all lack clinical evidence to support efficacy. Percepta® has robust patent protection and highly promising research results.

Percepta has the potential to be the category leader in this fast growing $8.6b market with human evidence to support outcomes and the funding of future studies that could lead to FDA botanical drug status which is the ultimate goal.

This IP-NFT represents a world’s first tokenization of a robust patent portfolio and a world’s first tokenized crowdsale for a clinical evidence study.

Success with this study can lead to future trials that create the potential for FDA botanical drug approval, potentially unlocking broad access to improve brain health globally.

Team

Mark Melnykowycz

Research Lead

Organisation

Cerebrum DAO

Experiment Cost

$405,250.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

The project has conducted experiments in disease-relevant rodent models demonstrating early efficacy with measurable outcomes including reduced amyloid plaque load, decreased neuroinflammation, and improved memory performance. These in vivo results in validated Alzheimer's disease animal models, combined with strong in vitro target engagement data (69.6% reduction in amyloid-beta aggregation, 85.7% reduction in tau aggregation), establish proof-of-concept beyond TRL 2's simplified systems.

Assessment

High Confidence

RecommendationPROMOTE

Total Score4.10

Overall Assessment

The project scores 4.10/5.00, indicating strong overall positioning at TRL 3. Key strengths include robust intellectual property (12+ patents), compelling preclinical validation with quantitative data demonstrating significant amyloid and tau aggregation reduction, and progression to IRB-approved human trials. The botanical formulation has established safety history and manufacturing feasibility. Primary areas for improvement include demonstrating human clinical efficacy (trial underway), expanding therapeutic optionality documentation, and clarifying regulatory pathway if pursuing drug vs. supplement route. The project is well-positioned for transition to TRL 4-5 pending clinical trial results expected in 2026.

Weighted Score

Price of CLAW

$0.110

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$CLAW	USD	ETH	From

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

Assessment

High Confidence

RecommendationPROMOTE

Total Score4.10

Overall Assessment

Weighted Score

Therapeutic Relevance

Strong therapeutic relevance for MCI/early cognitive decline. Mechanism targets amyloid-beta and tau aggregation with preclinical validation showing 69.6% reduction in amyloid fibril formation and 85.7% reduction in tau aggregation. Published in Nature Scientific Reports. Clear biological rationale linking cat's claw polyphenols and oolong tea to neuroinflammation and oxidative stress reduction.

Therapeutic Optionality

Primary focus is MCI and early cognitive decline. Some optionality exists for broader neurodegenerative conditions (Alzheimer's prevention) and general brain health supplementation, but specific expansion indications are not clearly articulated beyond the current cognitive health focus.

Intellectual Property

Robust IP portfolio with 12+ core patents secured since 2017 under Cognitive Clarity patent portfolio protecting the proprietary PTI-00703 Cat's Claw and MemorTea formulation. First tokenized brain health patent portfolio demonstrates innovative IP strategy. Strong defensible position.

Utility Of Candidates

Strong preclinical evidence with quantitative data showing significant target engagement in vitro. Rodent studies demonstrate reduced amyloid plaque load, decreased neuroinflammation, and improved memory. 2021 comparative study outperformed 20+ competitors. However, human efficacy data still pending from IRB-approved trial.

Prospects For Safety

Botanical ingredients with established dietary use history. No safety concerns identified in preclinical models. Small-scale commercial production already operational for supplement market indicating safe human consumption. Adverse event monitoring protocols established for clinical trial. Full toxicology studies not detailed.

Prospects For Gmp Cmc

Small-scale commercial manufacturing already operational demonstrating manufacturing feasibility. Botanical sourcing established. However, if pursuing FDA botanical drug pathway, additional GMP scale-up and CMC documentation would be required beyond current supplement-grade production.

Prospects For Clinical Development

IRB approval secured with clear trial design (n=154, 6-month RCT). Well-defined endpoints including digital MoCA, pTau-217 biomarkers, and wearable data. Decentralized trial design enables efficient recruitment. Team experienced with timeline through Q4 2026. IRB noted potential IND requirements; regulatory pathway via FDA botanical drug route considered.

Commercial Potential

Large target market (10M+ US, 50M+ global with early cognitive decline). Brain health supplements market $8.6B growing 13.3% annually. Clear commercial differentiation through human evidence-backed claims. Competitor Prevagen demonstrates $200M+ sales potential. However, supplement market is competitive with regulatory limitations on claims.

Organization And Team Fit

Strong team with PI Dr. Mark Melnykowycz, scientific founder Dr. Alan Snow, and experienced CRO partner Reputable Health. $580K+ funding secured through innovative DeSci/IP-NFT model. Operational through BIO.xyz and Cerebrum DAO. Some team depth details limited in documentation.